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OBJECTIVE: Health related quality of life (HRQOL) has been
shown to be an important predictor of survival in patients with
cancer. The aim of this study is to evaluate the role of serial mea-
surements of HRQOL in predicting survival for newly diagnosed
localized prostate cancer patients. METHODS: Data from
CaPSURE, a longitudinal disease registry of men with prostate
cancer, was used to identify a study population. HRQOL were
measured by SF-36 and were assessed bi-annually by mailed
questionnaires. All-cause mortality was reported by treating
physician or next-of-kin and conﬁrmed by death certiﬁcates. To
account for changes in HRQOL over time Cox proportional
hazards regression with time-dependent covariates analysis was
conducted. Univariate Cox proportional hazards model was ﬁt
for each HRQOL domain to determine which were related to
survival time. We then ﬁt a multivariate model using the
HRQOL domains found to be signiﬁcantly related to survival
time and also controlled for baseline clinical risk and age at diag-
nosis. Categorical variables were created for HRQOL based on
the baseline distribution of the lower 10th percentile and the
reminder of the patients. RESULTS: A total of 5610 patients met
the study criteria and 322 (5.6%) patients had died. Mean sur-
vival time (deﬁned as time from treatment to either death or last
follow up) was 33.3 months. Lower scores on Physical Function,
Role Physical, Role Emotional, Vitality, Mental Health, Social
Function, Bodily Pain and General Health were strongly associ-
ated with death (HR between 2.9 to 5.6). In multivariate analy-
ses Physical Function, Role Physical and General Health
remained signiﬁcantly associated with survival (HR = 2.0, 95%
CI = 1.4–2.8; HR = 1.9, 95% CI = 1.3–2.6; HR = 1.9, 95% CI
= 1.4–2.5 respectively). CONCLUSIONS: Lower scores on serial
measurements of physical and general health domains appear to
be signiﬁcant predictor of survival even when controlling for
known clinical factors.
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OBJECTIVE: The objective of this study was to analyze the mea-
surement properties of the EORTC QLQ-BR23, a breast cancer
speciﬁc module in measuring the health related quality of life.
METHODS: A structured literature review was performed. Arti-
cles were searched on MEDLINE, HEALTHSTAR, Science Cita-
tion Index, Google Scholar Search and on the websites of
National Cancer Institute, Centers for Disease Control and the
EORTC Quality of Life group. The MeSH headings used were
“Breast neoplasm, Quality of life and EORTC”. We included
randomized or non-randomized studies which had used the
QLQ-BR23 alone or in conjunction with other instruments.
Studies had to be published in English language between the
years 1990 to 2005. Reviews and methodological studies were
excluded. We included articles describing the following mea-
surement properties: reliability (internal consistency), validity,
and interpretability. Both discriminative and evaluative proper-
ties were also reviewed. The deﬁnitions of measurement proper-
ties were explicitly deﬁned a priori according to previous sys-
tematic reviews. RESULTS: Of the 68 papers cited, 21 were
extracted for detailed review. Overall, the instrument exhibited
high internal consistency (r > 0.70) in the dissimilar populations.
Reliability and interpretability were poorly addressed in the cited
studies. The QLQ-BR23 demonstrates face and content validity.
All the domains, except systemic therapy side effects, conﬁrmed
convergent-divergent validity. Construct validity for all the
domains was illustrated using the method of Known Groups
comparisons, in 6 culturally diverse populations, where the
QLQ-BR23 was used as a discriminating tool. Construct valid-
ity for evaluative properties was demonstrated only for the fol-
lowing domains: body image, breast symptoms and systemic
therapy side effects. CONCLUSION: EORTC QLQ-BR23 is
valid cross culturally and has high internal consistency. It has
good discriminative properties however evaluative properties
need more empirical support before we interpret data from lon-
gitudinal trials with conﬁdence.
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OBJECTIVES: This study assessed whether baseline and short-
term patient-reported quality of life (QOL) differs in patients
with symptomatic metastatic prostate cancer undergoing pallia-
tive management using opioids, non-steroidal anti-inﬂammatory
agents (NSAIDs), 89Sr chloride and 153Sm-lexidronam.
METHODS: Patients [n = 120] with metastatic prostate cancer
[prostatic adenocarcinoma] who had recently [within 2 months]
failed hormonal [e.g. leuprolide acetate] chemotherapy were
entered in this study following informed consent. Sociodemo-
graphic characteristics and PSA were not different between
patients by palliative management option. All patients had evi-
dence of bone metastasis on bone scans. The patients varied in
age between 55 to 76 years [overall mean 69.1 ± 11.3 years].
Patients were entered in the study that sought care for bone pain
due to prostate cancer [ICD-9-CM 185]. Males were grouped
according to primary palliative intervention: opioids (n = 40),
NSAIDs (n = 40), 89Sr chloride (n = 25), 153Sm-lexidronam (n
= 25). The short form of the self-administered McGill Pain Ques-
tionnaire (MPQ-SF) was used to measure QOL at baseline, 4
weeks, and 8 weeks after initiation of treatment. Clinical data
were collected from patients’ medical records. Statistical analy-
ses were conducted using descriptive methods and the Student’s
t-test. RESULTS: A signiﬁcant increase in the sensory pain rating
was observed in the patients treated by NSAIDs (+21%) and
89Sr (+46%) whereas those treated by opioids (-27%) and
153Sm (-27%) demonstrated a signiﬁcant (p < 0.05) decrease in
this subscore. There was a longitudinal decrease in QOL over
time in patients treated by NSAIDs and 89Sr as measured by the
total pain rating score whereas those treated with the other
agents experience improved QOL. CONCLUSION: This study
demonstrates the improvement in QOL achieved using 153Sm-
lexidronam which is comparable to that achieved by opioids
during this observation interval.
